WRAL Tech Wire

Trimeris is no more; $35M merger with Massachusetts firm closes

The combined company is known as Synageva, which becomes a publicly traded firm through the deal. Trimeris was based in Durham.

Trimeris, Synageva value merger at some $35M in filing

The two biopharmaceutical firms file information about the proposed deal with the SEC. Synageva would control 75 percent of the merged company.

Trimeris to merge with Massachusetts biopharmaceutical firm

If the deal is consummated, privately held Synageva BioPharma will absorb the Durham-based AIDS drug firm and emerge as a public company.

Trimeris wins $4.9M settlement with Roche over HIV drug

The Durham-based company had been feuding with the drug giant, which manufacturers the AIDS drug Fuzeon.

Trimeris posts $20M profit for 2010, but HIV drug sales fall

Sales of Fuzeon declined to $88.4 million compared to $112.2 million in 2009, the Durham company says.

Trimeris to pay Novartis $2.5M, royalties to settle patent suit

In another agreement, Trimeris makes a deal with its partner in HIV drug Fuzeon sales and marketing that saves Trimeris more than $18 million for marketing and sales.

Buyout of lease on former HQ costs Trimeris $496,000

Developer of AIDS drug Fuzeon reports a profit even as global sales drop.

Trimeris' former HQ in Morrisville

Trimeris remains profitable even though Fuzeon drug sales slip

$12 million breakup fee drives up Trimeris earnings

Bad news for Trimeris - Sales plunge 37% for HIV drug Fuzeon

Biotech startup led by former Trimeris CEO expands deal with Roche

b3 bio, which was launched by Dani Bolognesi, secures more investment from drug giant as well as development funds.

Nasdaq threatens to de-list Trimeris stock

South Korean terminates $81M offer for Trimeris

Arigene, which had asked Durham-based drug firm for an extension of the Dec. 28 for deal, is pulling out of deal. More than 80% of Trimeris shareholders had accepted stock offer.